

Subba Digumarthy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11562517/publications.pdf>

Version: 2024-02-01

25
papers

10,554
citations

932766

10
h-index

752256

20
g-index

25
all docs

25
docs citations

25
times ranked

13457
citing authors

#	ARTICLE	IF	CITATIONS
1	Isolation of rare circulating tumour cells in cancer patients by microchip technology. <i>Nature</i> , 2007, 450, 1235-1239.	13.7	3,272
2	Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors. <i>Science Translational Medicine</i> , 2011, 3, 75ra26.	5.8	2,938
3	Detection of Mutations in <i>EGFR</i> in Circulating Lung-Cancer Cells. <i>New England Journal of Medicine</i> , 2008, 359, 366-377.	13.9	1,602
4	<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. <i>Clinical Cancer Research</i> , 2016, 22, 4585-4593.	3.2	977
5	Molecular Mechanisms of Resistance to First- and Second-Generation <i>ALK</i> Inhibitors in <i>ALK</i> -Rearranged Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 1118-1133.	7.7	919
6	Heterogeneity Underlies the Emergence of <i>EGFR</i> T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. <i>Cancer Discovery</i> , 2015, 5, 713-722.	7.7	429
7	Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in <i>STK11</i> - and <i>KEAP1</i> -Mutant Lung Adenocarcinoma Is Affected by <i>KRAS</i> Mutation Status. <i>Journal of Thoracic Oncology</i> , 2022, 17, 399-410.	0.5	151
8	Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. <i>Oncologist</i> , 2013, 18, 1214-1220.	1.9	119
9	Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib. <i>JAMA Oncology</i> , 2016, 2, 541.	3.4	49
10	Type I Collagen-targeted Positron Emission Tomography Imaging in Idiopathic Pulmonary Fibrosis: First-in-Human Studies. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 258-261.	2.5	41
11	Assessment of chest CT at CTDI _{vol} less than 1 mGy with iterative reconstruction techniques. <i>British Journal of Radiology</i> , 2017, 90, 20160625.	1.0	10
12	Radiation dose reduction in chest dual-energy computed tomography: effect on image quality and diagnostic information. <i>Radiologia Brasileira</i> , 2018, 51, 377-384.	0.3	9
13	Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKI).. <i>Journal of Clinical Oncology</i> , 2012, 30, 7524-7524.	0.8	9
14	Phase 2 study of tremelimumab plus durvalumab for previously-treated malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2019, 37, 8549-8549.	0.8	9
15	Potential Pitfall in the Assessment of Lung Cancer with FDG-PET/CT: Talc Pleurodesis Causes Intrathoracic Nodal FDG Avidity. <i>Lung Cancer International</i> , 2013, 2013, 1-6.	1.2	6
16	Variation in mechanisms of acquired resistance (AR) among EGFR-mutant NSCLC patients with more than one post-resistant biopsy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8053-8053.	0.8	6
17	Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score $\geq 90\%$.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9111-9111.	0.8	4
18	Primary Paratracheal Leiomyoma: Increased Preoperative Diagnostic Specificity With Magnetic Resonance Imaging. <i>Annals of Thoracic Surgery</i> , 2016, 102, e151-e154.	0.7	2

#	ARTICLE	IF	CITATIONS
19	Multifocal adenocarcinoma of the lung: Factors predictive for local therapy.. Journal of Clinical Oncology, 2017, 35, e20041-e20041.	0.8	1
20	Phase I/II investigator-initiated study of olaparib and temozolomide in SCLC: Updated analysis and CNS outcomes.. Journal of Clinical Oncology, 2022, 40, 8565-8565.	0.8	1
21	Response to immune checkpoint inhibition as monotherapy or in combination with chemotherapy in metastatic ROS1-rearranged lung cancers.. Journal of Clinical Oncology, 2021, 39, 9049-9049.	0.8	0
22	Abstract LB197: An SU2C-Mark Foundation Lung collaborative update: integrative genomics identifies distinct transcriptional states associated with checkpoint blockade resistance. , 2021, , .		0
23	Longitudinal analysis of plasma ALK mutations during treatment with next-generation ALK inhibitors.. Journal of Clinical Oncology, 2019, 37, 9068-9068.	0.8	0
24	Efficacy of platinum-pemetrexed combination chemotherapy in ALK<i>+</i> non-small cell lung cancer refractory to second-generation ALK TKIs.. Journal of Clinical Oncology, 2019, 37, 9067-9067.	0.8	0
25	Abstract 3580: Integrative genomics of checkpoint blockade response in advanced non-small cell lung cancer. Cancer Research, 2022, 82, 3580-3580.	0.4	0